Daffodills Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.50 Cr
as on 17-07-2024
- Paid Up Capital ₹ 3.23 Cr
as on 17-07-2024
- Company Age 39 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.38 Cr
as on 17-07-2024
- Revenue 31.92%
(FY 2023)
- Profit 11.89%
(FY 2023)
- Ebitda -79.52%
(FY 2023)
- Net Worth 5.89%
(FY 2023)
- Total Assets 19.36%
(FY 2023)
About Daffodills Pharmaceuticals
The Corporate was formerly known as Daffodills Pharmaceutical Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.50 Cr and a paid-up capital of Rs 3.23 Cr.
The company currently has active open charges totaling ₹5.38 Cr.
Pranav Chaudhary, Prateek Chaudhary, Kunwar Singh, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24233UP1985PLC007205
- Company No.
007205
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 May 1985
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Meerut, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Daffodills Pharmaceuticals?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pranav Chaudhary  | Director | 22-Feb-2012 | Current |
| Prateek Chaudhary | Director | 22-Feb-2012 | Current |
| Kunwar Singh | Whole-Time Director | 30-Jul-2019 | Current |
| Prabhat Rai | Whole-Time Director | 30-Jul-2019 | Current |
| Prashant Chaudhry | Director | 02-Aug-2018 | Current |
Financial Performance of Daffodills Pharmaceuticals.
Daffodills Pharmaceuticals Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 31.92% increase. The company also saw a substantial improvement in profitability, with a 11.89% increase in profit. The company's net worth moved up by a moderate rise of 5.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Daffodills Pharmaceuticals?
In 2023, Daffodills Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Ell Pee Medicare Private LimitedActive 12 years 10 months
Pranav Chaudhary and Prateek Chaudhary are mutual person
Charges (Loans)
₹5.38 Cr
₹0
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 5.00 Cr
- U. P. Financial Corporation : 0.38 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Sep 2018 | Axis Bank Limited | ₹5.00 Cr | Open |
| 14 Oct 1995 | U. P. Financial Corporation | ₹3.80 M | Open |
How Many Employees Work at Daffodills Pharmaceuticals?
Daffodills Pharmaceuticals has a workforce of 11 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Daffodills Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Daffodills Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
